Evidence that angiotensin II, endothelins and nitric oxide regulate mitogen-activated protein kinase activity in rat aorta

European Journal of Pharmacology
T KuboY Hagiwara

Abstract

We measured the activity of mitogen-activated protein (MAP) kinases, enzymes believed to be involved in the pathway for cell proliferation, in rat aortic strips with or without endothelium, and examined effects of angiotensin receptor antagonists, endothelin receptor antagonists and nitric oxide (NO)-related agents. Endothelium removal produced an activation of MAP kinase activity in the strips, whereas the enzyme activity was not affected in the adventitia. The MAP kinase activation was inhibited by either the angiotensin AT1 receptor antagonist losartan or the endothelin ETA receptor antagonist BQ 123. The combination of both antagonists caused an additive inhibition. The angiotensin AT2 receptor antagonist PD 123,319 and the endothelin ETB receptor antagonist BQ 788 did not affect the MAP kinase activation. The NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) caused an activation of MAP kinase in the endothelium-intact aorta and the MAP kinase activation was inhibited by losartan or BQ123. The NO releaser nitroprusside inhibited the MAP kinase activation induced by endothelium removal or angiotensin II. These results suggest that even in isolated arteries, NO of endothelial origin tonically exert MAP kinase-in...Continue Reading

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·A RossomandoT W Sturgill
Dec 1, 1992·The American Journal of Physiology·K JanakideviA B Malik
Mar 1, 1990·The American Journal of Physiology·A BobikS Grinpukel
Jan 1, 1990·Journal of Cardiovascular Pharmacology·J S PowellH R Baumgartner
Oct 1, 1991·Hypertension·W OsterriederH R Baumgartner
Oct 17, 1991·Nature·B J PulvererJ R Woodgett
Apr 1, 1991·The Journal of Clinical Investigation·A J NaftilanV J Dzau
Feb 1, 1991·Trends in Pharmacological Sciences·P B TimmermansW F Herblin
Jan 1, 1990·General Pharmacology·J Marín, C F Sánchez-Ferrer
Oct 5, 1988·The American Journal of Cardiology·V J Dzau, G H Gibbons
Apr 1, 1995·Hypertension·C PeiróC F Sánchez-Ferrer
Dec 1, 1996·Japanese Journal of Pharmacology·K GotoY Kasuya

❮ Previous
Next ❯

Citations

Feb 13, 1999·European Journal of Pharmacology·T KuboR Fukumori
Nov 21, 2001·Current Opinion in Pharmacology·A P Davenport, J J Maguire
Jun 13, 2002·Clinical and Experimental Pharmacology & Physiology·Takao KuboRyuji Fukumori
Jan 6, 2016·Life Sciences·Maryam RameshradRohollah Fadaei Fouladi
Jan 31, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Daming ZhuangAviv Hassid
Dec 4, 2003·Circulation Research·Renate B Pilz, Darren E Casteel
Dec 4, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Daming ZhuangAviv Hassid
Dec 12, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Martin FlamantJean-Claude Dussaule
Jul 10, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Guo-Xing ZhangShoji Kimura
Apr 25, 2014·American Journal of Physiology. Cell Physiology·Mohammed Emehdi Atef, Madhu B Anand-Srivastava

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.